Cost of illness of metastatic prostate cancer: a perspective of costs for new treatment options in The Netherlands
Publication year
2017Source
Journal of Comparative Effectiveness Research, 6, 7, (2017), pp. 575-581ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Clinical Pharmacy
Journal title
Journal of Comparative Effectiveness Research
Volume
vol. 6
Issue
iss. 7
Page start
p. 575
Page end
p. 581
Subject
Radboudumc 4: lnfectious Diseases and Global Health RIHS: Radboud Institute for Health SciencesAbstract
AIM: To assess the resource use and associated costs of treating patients with metastatic prostate cancer with a focus on skeletal-related events (SREs). METHODS: We performed a bottom-up cost of illness study in The Netherlands. RESULTS: A total of 136 patients were studied. The mean total costs were euro17,931 per patient. SREs that required hospitalization (n = 53) were, at median costs of euro2039-9346, depending on care. These SREs had median costs of euro200-1912. CONCLUSION: Our data provide a basis to investigate the cost-effectiveness of novel treatment options for metastatic prostate cancer. The impact of SREs on total costs could justify policy aimed at actively preventing SREs, possibly resulting in better quality of life and cost-reduction.
This item appears in the following Collection(s)
- Academic publications [204887]
- Faculty of Medical Sciences [81046]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.